Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy

Min Zhang; Min Zhang; Yan Zou; Yan Zou; Xujun Zhou; Xujun Zhou; Jinming Zhou; Jinming Zhou

doi:10.3389/fimmu.2022.954129

Frontiers in Immunology (Sep 2022)

Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy

Min Zhang,
Min Zhang,
Yan Zou,
Yan Zou,
Xujun Zhou,
Xujun Zhou,
Jinming Zhou,
Jinming Zhou

Affiliations

Min Zhang: Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China
Min Zhang: Drug development and innovation center, College of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua, China
Yan Zou: Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China
Yan Zou: Drug development and innovation center, College of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua, China
Xujun Zhou: Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China
Xujun Zhou: Drug development and innovation center, College of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua, China
Jinming Zhou: Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China
Jinming Zhou: Drug development and innovation center, College of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua, China

DOI: https://doi.org/10.3389/fimmu.2022.954129
Journal volume & issue: Vol. 13

Abstract

Read online

The cGAS-STING signaling plays an integral role in the host immune response, and the abnormal activation of cGAS-STING is highly related to various autoimmune diseases. Therefore, targeting the cGAS-STING-TBK1 axis has become a promising strategy in therapy of autoimmune diseases. Herein, we summarized the key pathways mediated by the cGAS-STING-TBK1 axis and various cGAS-STING-TBK1 related autoimmune diseases, as well as the recent development of cGAS, STING, or TBK1 selective inhibitors and their potential application in therapy of cGAS-STING-TBK1 related autoimmune diseases. Overall, the review highlights that inhibiting cGAS-STING-TBK1 signaling is an attractive strategy for autoimmune disease therapy.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords